Abstract
ABSTRACT The occurrence of PC considerably worsens the prognosis of cancers. The classic treatment yields an overall survival of below 5% at 5years. However, in 20% of the cases, the disease is exclusively peritoneal, and a treatment combining complete cytoreductive surgery (CCRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) has made it possible to achieve a major increase in 5-year overall survival. HIPEC is only proposed for treating residual infra-millimetric,PC and therefore, is logical and useful exclusively after CCRS. The current appropriate indications are as follows: For peritoneal pseudomyxomas (5-year OSR is above 80%). For colorectal PC (5-year OSR exceed 40%, with 18% of patients definitively cured). For mesotheliomas (the 5-year OSR is close to 58%) Current doubtful indications are as follows: For gastric tumours (the 5-year OSR is close to 15%). For ovarian cancers (OSR are very low when CCRS + HIPEC is used as a salvage treatment). For few rare PC (not detailed). Conclusion CCRS + HIPEC are the current gold standard therapy for peritoneal extension of pseudomyxoma, mesotheliomas and colorectal PC, for selected patients. Disclosure The author has declared no conflicts of interest.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
